Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) reported $2.94 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 9.7%. EPS of $1.77 for the same period compares to $1.16 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.75 billion, representing a surprise of +7.11%. The company delivered an EPS surprise of +63.89%, with the consensus EPS estimate being $1.08.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Bausch + Lomb- Pharmaceuticals: $367 million compared to the $353.58 million average estimate based on two analysts. The reported number represents a change of +11.2% year over year.

• Revenues- Bausch + Lomb- Vision Care: $774 million versus the two-analyst average estimate of $770.83 million. The reported number represents a year-over-year change of +5.2%.

• Revenues- Bausch + Lomb- Surgical: $234 million compared to the $255.12 million average estimate based on two analysts. The reported number represents a change of +8.8% year over year.

• Revenues- Salix: $831 million versus $710.52 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.

• Revenues- International: $299 million versus $286.17 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.

• Revenues- Solta Medical: $165 million versus $169.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +17.9% change.

• Revenues- Diversified Products- Dentistry: $21 million compared to the $20.8 million average estimate based on two analysts. The reported number represents a change of -4.6% year over year.

• Revenues- Total Bausch + Lomb revenues: $1.38 billion versus the two-analyst average estimate of $1.38 billion. The reported number represents a year-over-year change of +7.3%.

• Revenues- Total Bausch Health (excl. B+L): $1.57 billion versus the two-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of +11.9%.

• Revenues- Diversified Products- Neuroscience: $146 million versus $112.32 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

• Revenues- Diversified Products- Dermatology: $86 million versus $53.22 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.2% change.

• Revenues- Diversified Products- Generics: $18 million compared to the $14.38 million average estimate based on two analysts. The reported number represents a change of +12.5% year over year.